A detailed history of Usa Financial Portformulas Corp transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Usa Financial Portformulas Corp holds 1,037 shares of CPRX stock, worth $23,498. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,037
Holding current value
$23,498
% of portfolio
0.0%

Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Jan 14, 2025

BUY
$19.73 - $23.93 $20,460 - $24,815
1,037 New
1,037 $21,000
Q3 2022

Oct 24, 2022

BUY
$7.06 - $15.52 $131,626 - $289,354
18,644 New
18,644 $239,000
Q2 2022

Aug 15, 2022

SELL
$6.23 - $8.57 $80,180 - $110,295
-12,870 Closed
0 $0
Q1 2022

Aug 16, 2022

SELL
$5.31 - $8.31 $85,496 - $133,799
-16,101 Reduced 55.58%
12,870 $107,000
Q4 2021

Feb 10, 2022

BUY
$5.21 - $7.45 $150,938 - $215,833
28,971 New
28,971 $196,000
Q4 2019

Feb 07, 2020

SELL
$3.67 - $5.7 $140,080 - $217,563
-38,169 Closed
0 $0
Q3 2019

Nov 14, 2019

BUY
$3.89 - $7.43 $148,477 - $283,595
38,169 New
38,169 $203,000

Others Institutions Holding CPRX

About CATALYST PHARMACEUTICALS, INC.


  • Ticker CPRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 102,820,000
  • Market Cap $2.33B
  • Description
  • Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...
More about CPRX
Track This Portfolio

Track Usa Financial Portformulas Corp Portfolio

Follow Usa Financial Portformulas Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Usa Financial Portformulas Corp, based on Form 13F filings with the SEC.

News

Stay updated on Usa Financial Portformulas Corp with notifications on news.